Royalty Pharma PLC
NASDAQ:RPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Royalty Pharma PLC
NASDAQ:RPRX
|
US |
|
G
|
Geekco Technologies Corp
XTSX:GKO
|
CA |
|
Lottery.com Inc
NASDAQ:LTRY
|
US |
|
T
|
Tessellis SpA
MIL:TSL
|
IT |
|
A
|
Avid Technology Inc
F:AVD
|
US |
|
Western Alliance Bancorp
NYSE:WAL
|
US |
|
C
|
Cooper Energy Ltd
OTC:COPJF
|
AU |
|
Brambles Ltd
ASX:BXB
|
AU |
|
M
|
Metals Australia Ltd
ASX:MLS
|
AU |
|
Television Francaise 1 SA
PAR:TFI
|
FR |
|
U
|
Unilever PLC
VSE:ULVR
|
UK |
Wall Street
Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for
RPRX
is 53.03 USD
with a low forecast of 46.46 USD and a high forecast of 64.05 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RPRX's stock price target?
Price Target
53.03
USD
According to Wall Street analysts, the average 1-year price target for
RPRX
is 53.03 USD
with a low forecast of 46.46 USD and a high forecast of 64.05 USD.
What is Royalty Pharma PLC's Revenue forecast?
Projected CAGR
16%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's revenue is
4%.
The projected
CAGR
for the next 3 years is
16%.
What is Royalty Pharma PLC's Operating Income forecast?
Projected CAGR
25%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's operating income is
2%.
The projected
CAGR
for the next 3 years is
25%.
What is Royalty Pharma PLC's Net Income forecast?
Projected CAGR
67%
For the last 7 years the
compound annual growth rate for
Royalty Pharma PLC's net income is
-8%.
The projected
CAGR
for the next 3 years is
67%.
